Editas Medicine Inc logo

EDIT

Editas Medicine Inc

$15.67

Earnings Summary

Revenue
$6.36Mn
Net Profits
$-53.45Mn
Net Profit Margins
-840.19%

Highlights

Revenue:

Editas Medicine Inc’s revenue jumped 1578.63% since last year same period to $6.36Mn in the Q2 2022. On a quarterly growth basis, Editas Medicine Inc has generated -6.04% fall in its revenue since last 3-months.

Net Profits:

Editas Medicine Inc’s net profit jumped 3.26% since last year same period to $-53.45Mn in the Q2 2022. On a quarterly growth basis, Editas Medicine Inc has generated -5.82% fall in its net profits since last 3-months.

Net Profit Margins:

Editas Medicine Inc’s net profit margin jumped 94.24% since last year same period to -840.19% in the Q2 2022. On a quarterly growth basis, Editas Medicine Inc has generated -12.62% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Editas Medicine Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.82
EPS Estimate Current Year
-0.82

Highlights

EPS Estimate Current Quarter:

Editas Medicine Inc’s earning per share (EPS) estimates for the current quarter stand at -0.82 - a -3.8% fall from last quarter’s estimates.

EPS Estimate Current Year:

Editas Medicine Inc’s earning per share (EPS) estimates for the current year stand at -0.82.

Key Ratios

Key ratios of the Editas Medicine Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.78
Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.34
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Editas Medicine Inc’s earning per share (EPS) jumped 3.86% since last year same period to -0.78 in the Q2 2022. This indicates that the Editas Medicine Inc has generated 3.86% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Editas Medicine Inc’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Editas Medicine Inc’s return on equity (ROE) stands at -0.34.

Dividend Per Share (DPS):

Editas Medicine Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
-0.82
-0.78
5.04%
2022-05-04
-0.79
-0.74
6.33%

Company Information

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Organisation
Editas Medicine Inc
Headquarters
Cambridge, Massachusetts, US
Employees
235
Industry
Health Technology
CEO
Cynthia Collins